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Purpose: The present study was intended to fabricate chitosan (Ch)-tamarind gum poly-
saccharide (TGP) polyelectrolyte complex stabilized cubic nanoparticles of simvastatin and 
evaluate their potential against human breast cancer cell lines.
Materials and Methods: The antisolvent precipitation method was used for formulation of 
nanoparticles. Factorial design (32) was utilized as a tool to analyze the effect of Ch and TGP 
concentration on particle size and entrapment efficiency of nanoparticles.
Results: Formulated nanoparticles showed high entrapment efficiency (67.19±0.42–83.36 
±0.23%) and small size (53.3–383.1 nm). The present investigation involved utilization of 
two biological membranes (egg and tomato) as biological barriers for drug release. The study 
revealed that drug release from tomato membranes was retarded (as compared to egg 
membranes) but the release pattern matched that of egg membranes. All formulations 
followed the Baker–Lansdale model of drug release irrespective of the two different biolo-
gical barriers. Stability studies were carried out for 45 days and exhibited less variation in 
particle size as well as a reduction in entrapment efficiency. Simvastatin loaded PEC 
stabilized nanoparticles exhibited better control on growth of human breast cancer cell 
lines than simple simvastatin. An unusual anticancer effect of simvastatin nanoparticles is 
also supported by several other research studies.
Conclusion: The present study involves first-time synthesis of Ch-TGP polyelectrolyte 
complex stabilized nanoparticles of simvastatin against MCF-7 cells. It recommends that, 
in future, theoretical modeling and IVIVC should be carried out for perfect designing of 
delivery systems.
Keywords: polysaccharide, polyelectrolyte, cubic nanoparticles, simvastatin, breast cancer, 
tamarind
Introduction
Abnormal growth and uncontrolled division of cells is known as cancer. Studies suggest 
that breast cancer is the second most common cancer after skin cancer. Breast cancer may 
spread into other organs of the body and becomes life-threatening.1 Conventional 
treatment of cancer involves radiotherapy, chemotherapy, and surgery. Several cancer 
treatment approaches are often ineffective, as attributed to their side-effects. Natural 
anticancer agents offering minimal side-effects are of great interest to many investigators. 
Studies suggest the anticancer potential of bio constituents of tamarinds seeds.2,3
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Simvastatin is now the second most significant reduc-
tase inhibitor in the class of compounds known as 
hydroxy-methylglutaryl-coenzyme, a reductase inhibitor 
researched in humans. Simvastatin is now being provided 
for periods of up to 2 years to over 1,800 patients for the 
management of hypercholesterolemia.4
In a study examining the effect of simvastatin on 
hepatocellular carcinoma, it was observed that simvastatin 
induces G0/G1 arrest by upregulation of p21 and p27 by 
activation of AMPK and inhibition of the STAT3-Skp2 
axis, respectively.5
Simvastatin also triggered caspase-dependent apoptosis 
in A549 lung cancer cells, where that was associated with 
decreased expression of phosphorylate Akt and low- 
regulatory survival of mRNA and protein.6 Another 
research study on prostate cancer using microarrays 
demonstrated that simvastatin therapy resulted in an up- 
regulation of Annex A10 (ANXA10) in PC-3 cells. 
ANXA10 is assumed to also have anti-tumor effects.6
Tamarind (Tamarindus indica) belongs to the Fabaceae 
family and is widely distributed in India, especially South 
India. The tamarind gum polysaccharide (TGP) is 
extracted from the kernel of tamarind seeds. The TGP is 
also known as galactoxyloglucan and its molecular weight 
is around 52,350 D, which constitutes about 60% of the 
total seed content.7 The TGP exhibits good gelling ability 
and muco-adhesion properties. The TGP is used as 
a carrier for oral and parenteral drug delivery systems.8,9 
In liquid dosage form, TGP has been used as suspending, 
emulsifying, and thickening agents. Moreover, TGP is also 
known for its nontoxic, biodegradability and biocompat-
ibility properties.10 As discussed by authors in previous 
studies, a major component of tamarind seed pulp is car-
bohydrate (70.8%), followed by protein (3.1%) and fiber 
(3.0%). Tamarind seed polysaccharide consists of the -OH 
group attached with cyclic structure. Galactose, xylose, 
and glucose are present in a 3:1:2 molar ratio. This ratio 
predicts that galactose is the major component of tamarind 
seed polysaccharide followed by glucose and xylose.9,11,12
Chitosan (Ch) is obtained from chitin. Crustacean and 
insect cuticle exoskeletons are known as rich natural 
sources of chitin. Chitin a natural biopolymer, is also 
found in fungal cell walls and mollusk shells.13 Tailoring 
of Ch by involving amino, acetamide, or hydroxy groups 
can generate derivatives with improved solubility and 
remarkable anticancer activity.14,15
Studies have shown that both Ch and its derivatives 
selectively permeate through cancer cell membranes and 
exhibit anticancer activity via enzymatic, immunoenhan-
cing, antiangiogenic, antioxidant defense mechanisms, and 
the apoptotic pathways of cells.15 Wimardhani et al's study 
revealed that cell cycle arrest and induction of apoptosis is 
the basic reason behind the anticancer activity of Ch.16
The hydrophobicity of therapeutic agents limits the 
bioactivity of potential biological molecules. Drug bioa-
vailability is a major concern for the therapeutic efficacy 
of anticancer drugs.17,18
Investigation suggests that nanoparticles are 
a promising tool for enhancement of cancer treatment 
because of their bioavailability enhancement property.19 
Nanoparticles are reported to enhance the bioavailability 
of less water-soluble drugs and prevent their degradation 
from various environmental factors. Nano-encapsulation is 
a novel approach to improve the solubility of dissolution 
controlled hydrophobic biologically active compounds.20
Since the last century, polyelectrolyte complex (PEC) 
based drug delivery systems have attracted researchers on 
the basis of their pharmaceutical and biomedical applica-
tions. One study reported the complex formation of Ch 
with a natural polymer (alginate) to retard the swelling and 
erosion of Ch that leads to retardation in drug release.21 
The PEC formation is a novel strategy used to elevate the 
biological and pharmaceutical properties of polymers.22
The PEC formation and nanotechnology approach, 
combined, have been used by researchers to improve the 
bioavailability of active pharmaceutical ingredients -
(APIs).23 Rajabi et al developed Ch-gum Arabic polyelec-
trolyte based nanocarriers for the delivery of saffron 
bioactive compounds. Prepared nano capsules were sphe-
rical in shape, with a diameter of about 193 nm.24 When 
oppositely charged macromolecules are allowed to interact 
with each other, polyelectrolyte or poly salt complexes are 
formed. Between oppositely charged molecules, like drug- 
polymer or polymer-polymer or polymer-drug-polymer, 
a few association complexes are formed, which are called 
PECs. Between these oppositely charged polyelectrolytes 
the electrostatic interaction may take place.25 PECs have 
been used to prepare systems for drug delivery.26
Structurally, these are neutral polymer-polymer com-
plexes consisting of macromolecules with opposite 
charges causing the electrostatic interactions to bind 
macromolecules together. In PEC formation, ion dipole 
interactions, hydrogen bonding and hydrophobic interac-
tions play a major role. This complexity leads to the loss 
of polymer chain conformation and translational entropy 
that must be counter-balanced. Electrostatic force is 
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considered a major contributor to the formation of PECs. 
However, other components of hydrogen bonding in 
dipole forces and hydrophilic interaction also significantly 
contribute to their complexation process.27,28 When low 
molecular weight counter ions are released, there is a gain 
in entropy. It is the main driving force for complex for-
mation. In recent decades, researchers have tried to 
develop PEC stabilized nanoparticles for drug delivery. 
The shape of the nanoparticles is a key factor that affects 
biodistribution, bio-circulation, cellular penetration, and 
targeting sites. In most of the cases nanoparticles are 
spherical in shape, maybe due to less awareness about 
the effect of shape of formulation on therapeutic effect 
and simplicity of process. Recently, the focus of biomedi-
cal scientists, globally, has shifted towards the shape- 
specific fabrication of nanoparticles. The shape of nano-
particles also dictates the fate of pharmacokinetics and 
pharmacodynamics of active pharmaceutical ingredients. 
In recent decades, the formulation of cubic nanoparticles 
has attracted much attention. Fabrication of cubic nano-
particles has tuned the association of particles with specific 
receptors. Research claims that the PRINT method has 
been used to prepare cube-shaped nanoparticles. Also, 
the solvent–antisolvent precipitation method assists in the 
preparation of spherical nanoparticles.29,30
It was observed that none of the researchers used 
solvent–antisolvent precipitation method for the fabrica-
tion of Ch-TGP polyelectrolyte stabilized cubic nanoparti-
cles. Interaction between the amino group of Ch and the 
hydroxyl group of TGP leads to formation of PECs. As 
PECs are formed between biocompatible, biodegradable, 
and nontoxic polymers, they are expected to offer good 
bio-acceptability. Self-organization, reversible and sponta-
neous association between oppositely charged molecules 
without covalent cross-linkers is a distinguished feature of 
formed PECs. Formed PECs are biodegradable, biocom-
patible, and non-toxic in nature. The study of Verma et al 
found that formation of PECs between poly acid and poly 
base leads to the formation of crystal-like structures.31
Keeping with the idea of Verma et al, it was expected 
that Ch- and TGP-based PECs will produce crystalline 
nanoparticles.31 As per our knowledge, it was the first 
attempt to explore the formulation of Ch-TGP polyelec-
trolyte stabilized crystalline nanoparticles for therapeutic 
application. Limited information was found on the effect 
of shape of polyelectrolyte stabilized nanoparticles on 
human cancer cells. In the present study, an attempt was 
made to investigate the effect of cubic nanoparticles and 
needle-shaped pure drugs in human breast cancer cell 
lines. The outcomes of the study will surely provide 




The chemicals, reagents and solvents were obtained from 
Merck Specialties, Sigma Aldrich, S D Fine Chemicals 
Limited, Fisher Chemicals, and HiMedia. Chitosan (med-
ium molecular weight, 75–85% deacetylated) was pro-
cured from Sigma Aldrich, St. Louis, USA).
Extraction of Tamarind Gum 
Polysaccharide
The testa (seed coat) of the seeds of tamarind was removed 
by drying them in a hot air oven for 20 min at 40°C. Next, 
the seed coating was removed by simply crushing the 
seeds from one side. Obtained white portions of the 
seeds were then utilized for the isolation of gum. The 
inner white part of seeds was immersed in a beaker with 
double-distilled water and heated at 40°C for 2 h. The 
supernatant fluid was discarded after centrifugation. 
Further, the remaining portion was concentrated by again 
heating at a constant temperature of 40°C. The slurry was 
filtered, and filtrate was precipitated using ethyl alcohol. 
The precipitated product was spread on the petri dish, 
dried and the size was reduced till a fine powder was 
obtained. Size reduction was carried out using a pestle 
and mortar. The powder was passed through sieve #22 
and stored for further use.32
Factorial Design
The 32 factorial design was used to prepare nanoparticles. 
In the present research, TGP and Ch concentrations were 
selected as independent variables; for dependent variables, 
particle size and entrapment efficiency were selected. 
Three levels were selected for every independent variable, 
as shown in Table 1. The NCSS 12 software (Trial version 
15/05/2018) was used for the analysis of dependent 
variables.33
Preparation of PEC Stabilized 
Nanoparticles
Nanoparticles were formulated using various concen-
trations of TGP and Ch, as shown in Table 1. 
Solutions of 20 mL TGP and 20 mL of Ch were 
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prepared separately in distilled water and 5% glacial 
acetic acid, respectively. TGP solution was further 
transferred into Ch solution and stirred for 20 min at 
40°C and for a further 5 min at 50°C. Simvastatin 
solution (1 μg/1 mL) was prepared using acetone as 
solvent. For the preparation of simvastatin solution, 
10 mg simvastatin was solubilized into 10 mL of acet-
one, followed by serial dilution to prepare 1 μg/1 mL 
solution. The drug solution (5 mL) was further added 
dropwise into the previously prepared TGP-Ch solution 
(PEC solution) using a syringe (BD Emerald, 5 mL). 
Next, the solution was stirred for 45 min at 65°C. 
Finally, the sample was cooled to 35°C and kept in 
an airtight container.34 Prepared samples consisting of 
dispersions of nanoparticles were used for further study 
and nanoparticles were not separated from the 
dispersions.
In the present investigation, simvastatin solution (1 μg/ 
1 mL) was prepared using acetone as solvent. For the 
preparation of simvastatin solution, 10 mg simvastatin 
was solubilized into 10 mL of acetone, followed by serial 
dilution to prepare a 1 μg/1 mL solution.
Prepared samples consisting of a dispersion of nano-
particles (nanosuspension) were used for further study and 
nanoparticles were not separated from the dispersion. As 
the final formulation was nanosuspension, washing was 
not performed.
FTIR Spectral Analysis
Spectral analysis of native polymers (Ch and TGP), a drug 
(simvastatin) and a physical mixture of Ch, TGP and 
simvastatin was done to identify any interaction between 
drug and polymer. Analysis of all the compounds was 
done using OPUS software to record the spectra in the 
range 4000–400 cm−1.
Nanoparticles Evaluation
Based on the following parameters, the PEC-based nano-
particles were characterized.
Physical Appearance
All the nanoparticles prepared were visually checked for 
turbidity.35
Particle Size Study
Using Zetasizer (Malvern Instruments, model no. 2000), the 
particle size of the formulated nanoparticles was determined. 
Zeta potential was also determined along with particle size. 
For the analysis, a dilute solution of 1% was used.36 As 
discussed in various literatures, concentrated solutions may 
create problems during particle size analysis. In the present 
investigation, a zeta analyzer was used to determine the 
particle size of THE formulated nanosuspension. A zeta 
analyzer is based on the principle of dynamic light scattering 
(DLS). In the concentrated solution, multiple scattering may 
take place that further leads to false results. To avoid the 
chance of false measurement, dilute solutions are generally 
employed to determine the size of suspended particles.37,38
Surface Properties
The SEM is primarily used for the determination of the 
sample morphology. The morphology of the nanoparticles 
was analyzed by the Zeiss EVO 18 analyzer. The powder was 
coated with gold and then placed in a sample holder. 
Nanosuspensions were kept in a sample holder and dried 
under vacuum, before analysis to prepare powder. The sur-
face properties of PEC stabilized nanoparticles were deter-
mined by a different magnification process.39
Entrapment efficiency
Absorption analysis of all formulations was carried out 
via the drug calibration plot to measure entrapment efficiency 
(%). In order to calculate entrapment efficiency, equation 1 
was used. The freshly prepared 10 mL portion of the cooled 
nanosuspension was centrifuged in microcentrifuge at 
10,000 rpm for 10 min. The supernatant was extracted, and 
the quantity of un-incorporated drug was calculated based on 
absorption of supernatant solution at 238 nm recorded using 
a UV spectrophotometer (UV-1800, Shimadzu, Japan).40,41
Entrapment Efficiency %ð Þ ¼




Tomato membranes and egg-shell membranes were used 
to determine the drug release from different formulations 
prepared from PECs.42
Table 1 Concentration of TGP (% w/v) and Ch (% w/v) for the 
Preparation of Nanoparticles
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Membrane Preparation
Egg Membrane Preparation
The chicken egg was taken for the preparation of the egg 
membrane. An orifice was created at one end of the egg 
and the yolk was completely removed through the open-
ing. The egg shell was kept in a beaker containing 
a solution of distilled water and 0.1 N HCl (3:1 ratio). 
The egg shell containing calcium carbonate was released 
as foam when it came in contact with an acidic solution 
(equation 2). The temperature of the solution was raised to 
50°C, which created bubbles. The bubbles stopped after 45 
min and the foam disappeared. At last, only the egg 
membrane was left in the beaker.33
CaCO3þ2HCl! CaCl2þCO2þH2O (2) 
Preparation of Tomato Membrane
At the top of the tomato fruit a cross was made to release 
the pulp. The tomato was heated in a water bath at 50° 
C for 5 min and the membrane was then removed slowly 
and carefully.43
In vitro Drug Release
Formulation was enclosed in the biological membrane 
(tomato and egg membranes) and tied properly. To enclose 
the formulation, a 2 cm x 3 cm membrane was cut and 
used. Initially, drug release was carried out in 0.1N HCl 
for 2 h followed by release study in a phosphate buffer pH 
7.4 up to 24 h. The temperature of both mediums was 
maintained at 37±0.5°C during the study, at 25 rpm. 
A sample (5 mL) was withdrawn at fixed time intervals 
and the same volume of fresh buffer was added. A UV 
spectrophotometer (UV-1800, Shimadzu, Japan) at wave-
length 238 nm was used for the analysis. Equation 3 was 
used to determine drug release (%).32,44
Drug release %ð Þ ¼
Concentration in formulation�
Dilution factor� Bath volume
1000
� 100 (3) 
Kinetic Studies of Drug Release
It is always necessary to determine the dissolution 
profile of a formulation. Kinetic models are used to 
determine the dissolution of a drug from the formula-
tion in which the quantity of a dissolved drug is the 
function of time.45,46 Release kinetics can be influ-
enced by the particle size of drug, type of drug, and 
solubility of drug. Kinetic study ensured that 
dissolution was occurring in the proper manner. To 
study the kinetics of drug release from the controlled 
release formulation, statistical methods and model- 
dependent methods were used. Model-dependent 
approaches included zero order, first order, Hixson– 
Crowell, Higuchi, Baker–Lonsdale, and Korsmeyer– 
Peppas.47,48 To calculate the zero-order and first-order 
rate constants, equations 4 and 5 were used, 
respectively.
Qt ¼ Qo þ Kot (4) 
where Qt is the drug dissolved amount in time t; Q0 is the 
initial amount of drug in the solution; and K0 is the zero- 




¼   Kc (5) 
where K is the first-order rate constant (time-1).
Equation 6 was used to determine the rate constant of 
the Higuchi model.




2C   δCSð ÞCSt
r
(6) 
where Q is the released amount of the drug in time “t” per 
unit area A; C is the initial concentration of the drug; Cs is 
the solubility of the drug in the matrix media; and D is the 
drug molecule diffusivity.
To determine the kinetics of the Hixson–Crowell 







t ¼ κt (7) 
where W0 is the initial drug amount in the pharmaceutical 
dosage form and Wt is the remaining drug amount in the 
pharmaceutical dosage form at time t.
The release rate constant was determined by equation 8 
for the Korsmeyer–Peppas model.
Mt
M1
¼ Ktn (8) 
where Mt/M∞ is a drug fraction released at time t; k is the 
release rate constant; n is the release exponent; and κ 
(kappa) is a constant incorporating the surface volume 
relation.
Equation 9 was used to determine the rate constant for 
the Baker–Lonsdale model.
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¼ kt (9) 
where the release rate constant, k, corresponds to the 
slope.
Similarity Factor
In formulation and dossier preparation, the concept of the 
similarity factor (f2) has been widely adopted. Two new 
indices (f1 and f2) were proposed by Moore and Flanner to 
compare test dissolution profiles and a reference formula-










where f2 is the similarity factor; n is the observation 
number; and (Rt–Tt) is the difference between the value 
of test and reference products.
Stability Studies
The growth of the particle size of PEC-based nanoparticles 
was also measured at 25±2°C by determining the particles' 
size on the 1st, 7th, 14th and 21st days and the possible 
growth of crystals.50
At 40±2°C and 75±5% RH for 45 days, stability stu-
dies were carried out. In terms of particle size and entrap-
ment efficiency, the stability of formulations was 
determined.51
Anticancer Activity
Assessment of anticancer activity of samples was carried 
out at an anticancer screening facility, Tata Memorial 
Center, Mumbai, as described in previous studies.33,52,53
An in vitro cytotoxicity analysis of pure drug and 
optimized formulation T5 was performed against breast 
cancer cell lines (MCF7) at the anti-cancer drug screening 
facility (ACDSF) at ACTREC, Tata Memorial Centre, 
Navi Mumbai. Sulphorhodamine B (SRB) was employed 
for the activity.
In the present analysis, MCF-7 cells were incubated for 
24 h at 37 °C in 96-well microtiter plates. After inocula-
tion of the cell, the microtiter plates were incubated with 
5% CO2, 100% relative humidity and 95% air for 24 h at 
37°C prior to addition of experimental drugs. Initially, test 
samples were solubilized in dimethyl sulfoxide at 
100 mg/mL and diluted with water to 1 mg/mL and stored 
frozen prior to usage. A frozen concentrate (1 mg/mL) 
aliquot was thawed and dilutions of 2, 4, 8 and 10 μg/ 
mL test sample solutions were prepared. The plates were 
incubated for 48 h after the addition of the sample in the 
standard condition and, by the addition of cold trichloroa-
cetic acid (TCA), reaction was terminated again. The cells 
were fixed by the gentle addition of 50 µL of cold 30% (w/ 
v) TCA (final concentration, 10% TCA) and further incu-
bated at 4 °C for 60 min. The supernatant was discarded; 
the plates were washed with tap water five times and air 
dried. Sulphorhodamine B (SRB) solution (50 µL) at room 
temperature was added to each well at 0.4% (w/v) in 1% 
acetic acid and the plates were incubated for 20 min. 
Washing was done with 1% acetic acid solution for the 
removal of unbound dye and the plates were then dried. 
The bound stains were then eluted with 10 mM Trizma 
base and the absorbance was read on a plate reader at 
a wavelength of 540 nm with a reference wavelength of 
690 nm. Percentage growth inhibition was calculated as 
shown in equation 11:
Ti
C
� 100% (11) 
Statistical Analysis
Experimentation work was carried out in triplicate and 
obtained data was presented as an average of results with 
standard deviation. Data were subjected to one-way ana-
lysis of variance (ANOVA) and t-tests were applied to 
evaluate equality of means. A p-value of >0.05 was con-
sidered statistically insignificant.
Results and Discussion
Inter-chain interaction in the solvent between Ch and TGP 
leads to the formation of PECs driven by electrostatic 
interaction. Hydrogen bonding, dipole–dipole interaction 
and hydrophobic interaction also play an important role in 
the formation of PECs. Figure 1 shows the PEC formation 
between chitosan and tamarind gum polysaccharide.
The weak electrolyte and PEC formation of the Ch and 
TGP implies a reduction in the free energy of the system. It 
further improves the stability of the complex formed. All the 
PEC stabilized nanoparticles were prepared using TGP and 
Ch. As discussed in another study, for the complex forma-
tion, oppositely charged biopolymers are mixed in solution 
form. Concentration of polymers should be kept below gel-
ling point. So, in the present study, both Ch and TGP were 
used in very low concentrations to avoid gel formation.54 In 
the present research, a very low concentration of the drug 
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was used to investigate its unusual anticancer effect. In other 
research, investigators also used a very low concentration of 
the drug to identify its unusual effect.55
Most of the available information on nanoparticles is based 
on the spherical nature of nanoparticles. The solvent–antisol-
vent method maintains finer control over particle size distribu-
tion and is able to modulate particle geometry. Jindal et al 
identified that nanoparticles deviate from the spherical shape 
mainly due to solute–solvent or solute–solute interaction.56
Classically, nanoparticles were prepared by solvent eva-
poration and the emulsification method; in the present inves-
tigation, however, novel antisolvent methods were used for 
the preparation of PEC stabilized nanoparticles. In this 
method drug nano-precipitates were formed using the anti-
solvent system and further stabilized with PECs. IR interpre-
tation of TGP data is shown in Table 2. IR interpretation of 
simvastatin data is shown in Table 3. IR interpretation of 
chitosan data is shown in Table 4. IR interpretation of IR 
spectra of the physical mixture of Ch, TGP and simvastatin is 
shown in Table 5. Figures 2 and 3 show the IR spectra of TGP 
and simvastatin. Figure 4 shows the IR spectra of chitosan 
and Figure 5 shows the IR spectra of the physical mixture of 
Ch, TGP and simvastatin.
The IR spectra of TGP shows that it contains O-H stretch, 
COOH, C≡C stretch, C=C stretch, C-O, and N-H bend func-
tional groups. Results of the IR spectral study weres also 
supported by Chawananorasest et al's study showing that the 
average molecular weight of tamarind seed polysaccharide 
ranges from 700–880 kDa.9 The IR spectra of simvastatin 
shows that it contains N-H stretch, C-H stretch, C≡O stretch, 
C=C stretch, C-H bend, and C-N bend functional groups. The 
IR spectra of chitosan shows that it contains O-H stretch, 
COOH, C≡C stretch, C=C stretch, C-O, and N-H bend func-
tional groups. The IR spectra of the physical mixture of Ch, 
TGP and simvastatin shows that it contains COOH, C-H bend, 
C=C stretch, N-O stretch, C-O stretch, and C=C bend func-
tional groups. The IR spectra shows that, significantly, no 
interaction occurs between the functional groups of the physi-
cal mixture of Ch, TGP and simvastatin.
Factorial Design
In the present research,a 32 factorial design was used to 
evaluate the effect of independent variables (concentration 
of TGP and Ch) over particle size and the entrapment 
efficiency of nanoparticles (dependent variable). 
A reduced equation for measuring response (particle size 
and entrapment efficiency) with statistical significance for 
the 32 factorial design is shown as equation 12.
y ¼ b0 þ b1x1 þ b2x2 þ b12x1x2 þ b11x12 þ b22x22 (12) 
where Y = response of variables (dependent variables); b0= 
arithmetic mean response of nine batches; and b1= estimated 
Figure 1 Schematic representation of PEC formation between chitosan and tamarind gum polysaccharide.
Table 2 IR Interpretation of TGP
S.No. Wave Numbers (cm−1) Functional Groups
1 3616 O-H Stretch
2 2361 COOH
3 2115 C≡C Stretch
4 1646 C=C Stretch
5 1042 C-O
6 1515 N-H Bend
Table 3 IR Interpretation of Simvastatin
S.No. Wave Numbers (cm−1) Functional Groups
1 3645 N-H Stretch
2 2921 C-H Strech
3 1698 C≡O Stretch
4 1510 C=C Stretch
5 1384 C-H Bend
6 1271 C-N Bend
7 867 C-H Bend
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coefficient of factors X1. The coefficient corresponding liner 
effect (b1 and b2), interaction (b1) and quadratic effect (b1 and 
b2) were determined from the results of the experiment; and 
X1 and X2 are quantity of the polymers.
Solving equation 12 makes it possible to generate the 
effect of quantity of polymer over particle size (equation 
13) and the entrapment efficiency (equation 14) of 
nanoparticles.
PS ¼ 180:155þ 65:85 X1ð Þ þ 22:98 X2ð Þ þ 0:366 X1X2ð Þ
þ 30:52 X12ð Þ   2:11 X22ð Þ
(13) 
where PS = particle size in nm.
EP %ð Þ ¼ 76:77   1:72 X1ð Þ þ 0:46 X2ð Þ   1:03 X1X2ð Þ
  0:815 X12ð Þ þ 0:098 X22ð Þ
(14) 
In the present study, only two levels of each factor were 
shown in equations because the third level of each factor 
did not significantly affect the overall outputs of the inde-
pendent variables. To simplify the equation, only two 
levels are shown in the text.
The surface plots for effect of independent variables 
over size and entrapment efficiency of nanoparticles are 
shown in Figures 6 and 7, respectively.
Characterization of PEC Stabilized 
Nanoparticles of Simvastatin
The formulations of nanoparticles were prepared using PEC, 
checked visually and found to be clear. The prepared nano-
suspensions were found to be transparent without any pre-
cipitation (Table 6). The particle size of all formulations was 
observed to be in the range of 53.3 to 383.1 nm. The smallest 
particle size was observed in the case of formulation T5 
(53.3 nm) as it contains the lowest concentration of TGP and 
Ch. Formulation T1 shows the largest particle size, 383.1 
nm, which may be due to the highest concentration of TGP 
Table 5 IR Interpretation of IR Spectra of the Physical Mixture of 
Ch, TGP and Simvastatin
S. No. Wave Numbers (cm−1) Functional Groups
1 2361 COOH
2 1832 C-H Bend
3 1648 C=C Strech
4 1522 N-O Stretch
5 1108 C-O Stretch
6 758 C=C Bend
Table 4 IR Interpretation of Chitosan
S.No. Wave Numbers (cm−1) Functional Groups
1 3616 O-H Stretch
2 2361 COOH
3 2115 C≡C Stretch
4 1646 C=C Stretch
5 1042 C-O
6 1515 N-H Bend
Figure 2 IR spectra of TGP.
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and Ch. The surface volume ratio of the non-spherical 
particles (like cubic and rod-shaped) is less than that of the 
spherical particles. Results obtained in the present study 
were also supported by Oh et al's study, wherein the particles 
having a lower aspect ratio show better cytotoxicity.57
Perfect designing of nanoformulations should justify 
high entrapment efficiency, smaller particle size, no or less 
drug leaching and improved bioavailability. As discussed by 
many researchers, nanoparticles with a size range of less 
than 100 nm are capable of entering and remaining within 
tumor cells and have better therapeutic potential. Small size 
nanoparticles are selectively accumulated within the tumor 
cells when distribution takes place. A study by Jansch et al 
revealedha that the shape of the nanoparticles does not 
affect the protein binding of formulations.58 Moore et al 
found that particle sizes below 100 nm have the ability to 
drift towards the capillary wall (due to hydrodynamics) and 
show better cellular accumulation.59 Another study found 
that cellular internalization of nanorods was not signifi-
cantly altered by the aspect ratio.60 Circulation of non- 
spherical nanoparticles in blood is significantly affected by 
the orientation of particles in vessels. Vacha et al observed 
Figure 3 IR spectra of simvastatin.
Figure 4 IR spectra of chitosan.
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that surface adhesion energy is the key determining factor 
for the endocytosis of nanoparticles.61 The T5 was consid-
ered the optimal formulation as it has the lowest particle 
size (53.3 nm). The T5 was further used for the character-
ization of the in vitro anticancer effect. The potential differ-
ence on the surface of nanoparticles was determined. The 
zeta potential is the electrical potential at the slipping plane 
location in the interfacial double layer, which is a relative 
point in the bulk fluid away from the interface. The potential 
difference between the dispersion medium and the station-
ary layer of fluid attached to the dispersed particle is zeta 
potential. Zeta potential was observed in the range of 32.2 
mV to 34.3 mV. Formulation T1 shows the largest particle 
size but lowest zeta potential, 32.2 mV. It may be due to 
charge neutralization, as both TGP and Ch contain the high-
est concentration, so their charge neutralizes and results in 
Figure 5 IR spectra of the physical mixture of Ch, TGP and simvastatin.
Figure 6 Surface plot for effect of independent variables over size of nanoparticles.
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the lowest zeta potential. Highest zeta potential was 
observed in the case of formulation T6. The entrapment 
efficiency of all formulations was found to be greater than 
70% except in batch T1. Formulation T1 shows the highest 
entrapment efficiency, 83.36%, shown in Table 6. Batch T1 
consists of TGP and Ch in the highest concentration 
(Table 1).
The research study suggests that the dispersed nano-
suspensions are generally evaluated for their entrapment 
efficiency. This is because in dispersed nanosuspensions 
the nanoparticles are distributed in a solvent system and 
the drug loading capacity (equation 15) requires total 
weight of nanoparticles.
Loading capacity %ð Þ ¼
Entrapped drug
Nanoparticle weight
� 100 (15) 
Therefore, in this study the formulated nanoparticles were 
not separated out and were only evaluated for their entrap-
ment efficiency/% loading capacity.
Usually in dispersed nanosuspensions, the nanoparti-
cles are distributed in a solvent system and they are not 
separated out. This research aspect is also supported by 
several other researchers.62–64
The SEM image of prepared nanoparticles is shown in 
Figure 8. The scanning electron microscopy of the nanopar-
ticles reveals their crystal shape. The SEM images showed 
rough surfaces of Ch (Figure 8A) and TGP (Figure 8B). 
Particles were also observed in the SEM images of TGP 
(Figure 8B). Drug precipitates were found to be crystalline 
deposits (Figure 8C), while nanoformulation (T5) was found 
to be cubic in shape (Figure 8D). Operational voltage 
(15kV) was applied for SEM images of TGP (X15,000) 
and Ch (X15,000) and 30 kV for the SEM images of drug 
precipitates (X10,000) and nanoparticles (T5) (X27,000).
Karfa et al made comparisons between spherical-shaped 
and cube-shaped nanoparticles of Ag/AgCl. In their investi-
gation, it was observed that cube-shaped nanoparticles 
showed higher adsorption capacity to the receptor as com-
pared to spherical nanoparticles. This ability may occur due 
to the high surface area of a nanocube in comparison to 
a spherical nanoparticle.65 According to a study conducted 
by Zhao et al, cube-shaped nanoparticles are more stable 
than spherical nanoparticles.66 Another study, by Kolhatkar 
et al, found that cubic-shaped nanoparticles provide better 
therapeutic effects on binding that spherical nanoparticles.67 
So, in the present investigation, cube-shaped nanoparticles 
were prepared as the drug delivery carrier.
Figure 9 shows drug release of formulation through the 
egg membrane while Figure 10 shows drug release of for-
mulation through the tomato membrane. The release study 
was carried out for 24 h. It was observed that the release 
study through the egg membrane and the tomato membrane 
did not significantly alter the pattern of drug release. An 
initial burst release of the drug was observed at 15 min and 
90 min followed by sustained release of the drug for 
Figure 7 Surface plot for effect of independent variables over entrapment efficiency of nanoparticles.
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24 h. The retarded drug release was observed when the 
tomato membrane was used as a biological membrane in 
place of the egg membrane. Instead of retarded drug release 
through the tomato membrane, the basic release pattern 
remained the same as drug release through the egg mem-
brane. Generally, a dialysis membrane is used as a biological 
barrier to investigate drug release characteristics. In the pre-
sent investigation, a preliminary attempt was made to iden-
tify an alternative membrane for a drug release study. In 
future, further research will be needed into pore size, 
membrane stability, etc., in order to develop a new mem-
brane. A correlation between synthetic and proposed natural 
membranes will need to be developed. Investigators believe 
this first-time exploratory study into tomato membranes as 
a novel and alternative natural biological barrier will inform 
other drug release studies. In future, this membrane can be 
a novel biological model that canopen up avenues for further 
research.
Times of 50% drug release (T50%) and 80% drug 
release (T80%) are tabulated in Table 7.
Table 6 Characterization Parameters of PEC Stabilized Nanoparticles
Formulation Characterization Parameters
Physical Appearance pH Particle Size (nm) Zeta Potential (mV) Entrapment Efficiency (%)
T1 Clear solution 4.1±0.01 383.1 32.2 83.36± 0.23
T2 Clear solution 4.3±0.00 285.1 33.1 77.84±0.46
T3 Clear solution 4.3±0.01 306.0 32.6 73.22±0.32
T4 Clear solution 4.1±0.01 148.0 33.5 67.19±0.42
T5 Clear solution 4.1±0.01 53.3 33.4 71.01±0.36
T6 Clear solution 4.2±0.00 180.2 34.3 80.67±0.29
T7 Clear solution 4.2±0.01 103.3 35.2 82.29±0.23
T8 Clear solution 4.2±0.01 89.1 34.9 79.83±0.48
T9 Clear solution 4.2±0.01 73.3 33.6 75.54±0.46
Figure 8 SEM image of (A) Ch, (B) TGP, (C) drug precipitates and (D) nanoparticles-T5.
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From the kinetic study data (Tables 8 and 9), it was 
observed that the Baker–Lonsdale drug release model was 
followed by most of the formulations. After this model, the 
Higuchi model was followed as the obtained r2 value was 
greater than all other models except the Baker–Lonsdale 
model. The Baker–Lonsdale model was derived from the 
Figure 9 DR (%) of formulations via egg membrane (A) T1, T2, T3; (B) T4, T5, T6; and (C) T7, T8, T9.
Figure 10 DR (%) of formulations via tomato membrane (A) T1, T2, T3; (B) T4, T5, T6; and (C) T7, T8, T9.
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Higuchi model. The Higuchi model was also used by other 
researchers investigatingr nanoparticles.68,69 The Higuchi 
model is based on three hypotheses.70 First, initial drug 
concentration in the matrix is much higher than drug solu-
bility. Second, as particles are much smaller than system 
thickness, the drug particles are encapsulated inside the 
prepared nanoparticles and no drug is on the surface. 
Third, drug diffusivity is constant. The release occurs 
through pores in the matrix. This model follows the porous 
system, as hydrophilic polymer solubilizes easily and 
releases through pores.20
In the study, TGP was used as the polymer, which is 
hydrophilic and soluble when it comes in contact with the 
solvent system. Drug release through pores can be 
expressed by equation 16.





2C   δCsð ÞCst (16) 
Data predicts that the Baker–Lonsdale model is fol-
lowed by all formulations irrespective of the membrane 
Table 7 T50% and T80% of Prepared Nanoformulations









T1 85 320 125 150
T2 210 310 105 150
T3 15 270 125 160
T4 90 270 120 150
T5 70 140 210 225
T6 23 150 120 150
T7 125 160 135 165
T8 125 160 110 140
T9 55 125 90 130














R2 Ko R2 Ko R2 Ko R2 Ko R2 Ko R2 Ko R2
T1 0.389 0.043 0.103 0.0009 0.692 2.178 0.916 0.115 0.639 0.002 0.063 1.815 0.090
T2 0.5384 0.054 0.167 0.0011 0.726 1.482 0.895 0.092 0.642 0.003 0.010 2.207 0.095
T3 0.3537 0.041 0.091 0.0009 0.654 2.420 0.967 0.133 0.763 0.002 0.058 1.657 0.079
T4 0.3958 0.045 0.110 0.0011 0.707 2.096 0.907 0.112 0.642 0.003 0.073 1.893 0.073
T5 0.2541 0.043 0.094 0.0009 0.570 2.436 0.930 0.108 0.563 0.002 0.133 1.905 0.089
T6 0.2211 0.036 0.075 0.0011 0.540 2.930 0.965 0.112 0.559 0.002 0.153 1.676 0.123
T7 0.3614 0.045 0.108 0.0011 0.667 2.151 0.901 0.116 0.822 0.002 0.077 1.876 0.079
T8 0.3355 0.053 0.145 0.0011 0.646 1.716 0.925 0.060 0.783 0.003 0.129 2.795 0.067
T9 0.1942 0.045 0.108 0.0011 0.492 2.296 0.839 0.058 0.283 0.002 0.167 2.645 0.090














R2 Ko R2 Ko R2 Ko R2 Ko R2 Ko R2 Ko R2
T1 0.300 0.049 0.082 0.0009 0.617 1.920 0.925 0.071 0.656 0.003 0.103 1.637 1.638
T2 0.285 0.048 0.076 0.0009 0.605 1.978 0.946 0.066 0.640 0.002 0.123 1.606 1.606
T3 0.310 0.058 0.102 0.0011 0.616 1.489 0.750 0.028 0.625 0.003 0.145 2.067 2.068
T4 0.307 0.053 0.103 0.0009 0.625 1.719 0.927 0.044 0.663 0.003 0.133 1.989 1.990
T5 0.462 0.072 0.336 0.0018 0.639 1.139 0.522 0.011 0.673 0.003 0.402 5.869 5.869
T6 0.291 0.051 0.086 0.0009 0.609 1.848 0.934 0.055 0.641 0.003 0.127 1.746 1.746
T7 0.359 0.054 0.084 0.0009 0.780 1.641 0.928 0.057 0.696 0.003 0.088 1.808 1.808
T8 0.291 0.046 0.069 0.0009 0.608 2.054 0.953 0.073 0.695 0.002 0.084 1.482 1.482
T9 0.227 0.045 0.056 0.0006 0.536 2.244 0.953 0.072 0.470 0.002 0.164 1.407 1.408
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used in the study. The calculated similarity factor was 
found to be 16.82. This means that the membranes are 
dissimilar in their drug release as the value observed 
was less than 50. All formulations of nanoparticles were 
subjected to size analysis on the 7th, 14th and 21st days. 
The particle sizes of formulations after the mentioned 
days did not significantly differ from particle sizes on day 
1 (data given in Table 10). No crystal growth was 
observed as particle size analysis showed a single peak 
during the analysis.
The particle size of nanoparticles in each formula-
tion was found to be somewhat similar to the size of 
particles on day 1. This means that crystal growth had 
not yet started, so there was no increase in particle 
size. After the 14th and 21st days, the size of particles 
increases as compared to previous days due to crystal 
growth and accumulation. Potential differences on the 
surfaces of nanoparticles of formulations were ana-
lyzed on the 7th, 14th and 21st days and no significant 
deviation from initial readings was observed. After 14 
days of study, no significant differences (p ‹0.05) were 
observed in the particle size and zeta potential of 
nanoformulations. Entrapment efficiency and particle 
size data on the initial day and after 45 days are 
tabulated in Table 11. Data obtained from stability 
studies showed a slight increase in size (maybe due 
to crystal growth) and a decrease in entrapment effi-
ciency of nanoparticles (maybe due to leaching) after 
45 days.
Generally, statins (3-hydroxy-3-methylgutaryl CoA 
reductase inhibitors) are considered to provide curative 
effects in the treatment of cardiovascular diseases. 
Based on some of the preclinical studies, they are 
gaining interest as anticancer agents too.71 The effects 
of statins on the growth of breast cancer cells were 
evaluated. Statins have pleiotropic effects as a result of 
which they are gaining interest as anticancer agents.72 
Investigation of simvastatin was carried out on the 
propagation of human breast cancer cell line MCF-7. 
As well as a cholesterol-lowering effect, statins may be 
important the deterrence of human breast cancer. In 
MCF-7 cells, activity like caspase-3 and DNA frag-
mentation is enhanced by simvastatin by which MCF- 
7 cell propagation is inhibited. For the purpose of cell 
propagation, formation of mevalonate (cholesterol pre-
cursor) is required, catalyzed by HMG-CoA 
reductase.73 Growth of malignant cells can be damaged 
or weakened by inhibiting the synthesis of mevalonate. 
Simvastatin is reported to act as an osteolysis inhibitor 
in a mouse used as a model for breast cancer. 
Specifically, statins increase the apoptosis and 
Table 10 Particle Growth Analysis and Zeta Potential After 7th Day, 14th Day and 21st Day
Formulation Particle Size Growth (nm) Potential Difference (mV)
After 7 Days After 14 Days After 21 Days After 7 Days After 14 Days After 21 Days
T1 383.2 383.4 384.9 32.3 32.4 33.3
T2 285.1 285.3 287.3 33.2 33.4 34.9
T3 306.0 306.1 307.0 32.7 32.9 34.1
T4 148.1 148.6 150.1 33.6 33.8 34.8
T5 53.4 53.7 55.1 33.5 33.8 34.6
T6 180.2 180.3 181.9 34.4 34.6 36.1
T7 103.5 103.6 105.8 35.2 35.5 36.8
T8 89.2 89.5 91.1 35.1 35.2 37.0
T9 73.4 73.7 74.9 33.6 35.7 35.2
Table 11 Stability Study Parameters of Nanoformulations










T1 383 387 83.36±0.42 66.89±0.14
T2 285 289 77.84±0.46 77.02±0.29
T3 306 310 73.22±0.32 73.18±0.42
T4 148 155 67.19±0.23 82.99±0.26
T5 53 59 71.01±0.36 70.16±0.19
T6 180 186 80.67±0.29 79.21±0.46
T7 103 106 82.29±0.23 81.89±0.37
T8 89 94 79.83±0.48 79.12±0.25
T9 73 78 75.54±0.46 74.67±0.38
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radiosensitivity in different breast cancer cell lines, 
prevent proliferation and invasion, and decrease 
tumors' metastatic dissemination. Clinical findings 
show that statins minimize the recurrence rates of 
breast cancer when administered post- 
diagnostically.74,75 Many in vitro and animal studies 
indicate that statin drugs inhibit the development of 
breast cancer. Little evidence in human subjects sup-
ports a protective impact of statins on incidence of 
breast cancer, but consistent evidence supports 
a protective effect on recurrence of the disease.
As per the data given in Figure 11, T5 exhibits 
significantly higher death of human breast cancer 
cells (MCF-7) than pure drug in the in vitro condi-
tions. It may be due to the smaller size of prepared 
nanoformulations than the particle size of pure drug. 
Smaller size of nanoformulations leads to better dis-
solution hence their therapeutic potential. Phagocytes 
exhibit fewer tendencies for non-spherical nanoparti-
cles as compared to spherical nanoparticles. 
Attachment of elongated nanoparticles with cells with 
their axis also reduces the chance of phagocytosis. In 
their study, Huang et al demonstrated that aspect ratio 
of nanoparticles has a significant effect on internaliza-
tion, differentiation, proliferation, adhesion and migra-
tion when studied in human melanoma cells A375.76 
Godin et al evaluated the effect of spherical and non- 
spherical nanoparticles in murine model of breast can-
cer. They predicted that non-spherical particles would 
exhibit higher concentration than spherical particles 
within the breast cancer cells.77 Table 12 summarizes 
the outcomes obtained from the chitosan-based PEC 
nanoparticles.
Figure 12 shows the bright field image of (a) 
untreated MCF-7 cells, (b) MCF-7 cells treated with 
T5, and (c) MCF-7 cells treated with pure simvastatin.
Table 13 describes cell death (%) after the administra-
tion of pure drug and nanoparticles at different 
concentrations.
As discussed by Zhao et al, cytotoxicity of nano-
particles depends upon shape of the particles as well 
as types of cells used in the study.78 Hence, the pre-
sent study specifically exhibited the results obtained on 
the human breast cancer cell lines. The opposite result 
was observed by Li et al, as they concluded that 
cellular uptake of spherical nanoparticles is higher 
than cube- and rod-shaped particles due to the ease 
of the bending capability of the cellular membrane 
around the nanoparticles.79 The observation of Li 
et al was also supported by Shimoni et al, as they 
showed that HeLa cell accumulation towards various 
nanoparticles depends upon the aspect ratio of parti-
cles. HeLa cells preferably accumulate towards the 
particles having a smaller aspect ratio.80
Conclusion
The present study was based on identification of the 
need to determine the effect of crystalline drug parti-
cles and cubic nanoparticles on human breast cancer 
cell lines (MCF-7). It can be concluded from the study 
that the antisolvent precipitation method allows control 
over the fabrication of cubic nanoparticles. This study 
also recommends that the present method can be easily 
adopted to control the shape, edge geometry and 
aspect ratio of nanoparticles. The study shows that 
solid cubic nanoparticles can be prepared using the 
solvent–antisolvent method and by utilizing Ch-TGP 
as a polyelectrolyte complex forming agent. Fabricated 
PEC-based nanoparticles exhibit good entrapment effi-
ciency and ability to control drug release up to 
24 h. Prepared cubic nanoparticles exhibited better 
control over the growth of human breast cancer cell 
lines (MCF-7) than pure drug precipitates in in vitro 
conditions. Simvastatin is an established hypolipidemic 
agent. Simvastatin has low aqueous solubility. In the 
present research, nanoparticles were prepared to 
increase the solubility of simvastatin. The literature 
also shows that simvastatin has some anticancer Figure 11 Anticancerous activity of nanoparticles (T5) and pure drug precipitates.
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Table 12 List of Chitosan-based PEC Nanoparticles and Their Outcomes
Chitosan-based PEC Nanoparticles Outcome
Attallah et al prepared pectin/chitosan/jasmine oil nanoparticles (Pec/ 
CS/JO NPs) by using Box-Behnken design (BBD).81
The outcome was that pec/CS/JO NPs was effective against (MSF-7) 
breast cancer cells, which was evaluated by using MTT assay, where it 
was found that normal cells were not affected by the prepared 
nanoparticle.81
Guo et al formulated a chitosan-based nanogel to inhibit the 
proliferation of breast cancer cell lines, where the model drug of 10- 
hydroxycamptothecin (HCPT) was entrapped into core by facile 
diffusion to form chitosan/10-hydroxycamptothecin (CS/HCPT).82
From the prepared formulation the outcome was evaluated by 
assessing particle size, drug loading content and drug loading 
efficiency. Further cytotoxicity, apoptosis of CS/HCPT, was also 
investigated in vitro.82
Nascimento et al synthesized a delivery system in which non- 
targeted delivery was done of chitosan, polyethylene glycol and 
siRNA.83
The outcome showed that there was an inhibition in tumor tissues in 
animal model and faster elimination.83
Nascimento et al did another study and synthesized another delivery 
system for targeted delivery, which was done by chitosan, polyethylene 
glycol, RGFR-targeting peptide and siRNA.84
In this research combination therapy was used, where chitosan-based 
nanoparticles were combined with cisplatin in cancer models and tumor 
tissues.84
Jain et al developed a chitosan nanoparticle which was coupled with 
hyaluronic acid with the help of inotropic gelation method, where 
5-fluorouracil (5FU) was chosen as the drug and used for the colon 
cancer treatment.85
In the outcome, HA was incorporated in the chitosan nanoparticles 
drug delivery system due to an elevated level of HA receptors around 
tumor tissues. So, in the result, nanoparticles can target colon tumors 
via both EPR effect and binding of hyaluronic acid to HA receptors and 
chitosan-based nanoparticles were already loaded with 5-fluorouracil 
drug.85
Zhang et al reported a design of pH-mediated chitosan-based microgel 
DDS for treatment of cancer, where chitosan powder was dissolved in 
water and then it was reacted with Glycidyltrimethylammonium 
chloride to form N-[(2-hydroxy-3-trimethylammonium)propyl]chitosan 
chloride (HTCC). Further nanoparticles of HTCC were fabricated by 
ionotropic method.86
Methotrexate disodium was also loaded in HTCC and in the outcome 
of this research, it was found that in cell experiments MTX-loaded 
HTCC highest mortality rate of Hela cells and cancerous cells was 
found as compared to the pure drug group and non-conjugated MTX- 
chitosan nanoparticle group.86
Yang et al successfully formulated oxaliplatin and miRNA-205-5p loaded 
polyethyleneimine (PEI)/hyaluronic acid (HA) mesoporous silica-based 
nanoparticles (OXmi-HSMN). This formulation was made to improve 
therapeutic efficacy in colon cancers.87
In the research, when tumors were extracted from the mice and 
processed for TUNEL assay, it can clearly be seen in the assay that 
OXmi-HMSN encouraged apoptosis of tumor cells when compared to 
any other group which is producing a superior anticancer effect. OXmi- 
HMSN leads to inhibition of tumor growth which is greater than any 
other group, either OXL or OXL-MSN. So, their study provides the dual 
therapeutics for enhanced therapeutic efficacy in the treatment of colon 
cancer.87
Cui et al did research and formulated a T7-modified, magnetic PLGA 
nanoparticulate system (MNP/T7-PLGA NPs) through the process of 
single-emulsion solvent evaporation method, in which nanoparticles 
which are magnetic hydrophobic (MNPs) were entrapped into PLGA 
NPs.88
In the outcome of this research, when comparison was done 
between other conventional magnetic nanoparticles and these 
PLGA NPs, it was found that PLGA NPs are more beneficial due to 
their capability of co-encapsulation of various drugs. The efficiency 
of treatment was investigated both in vitro and in vivo.88
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activity with hypolipidemic potential. Therefore, the 
present research provides an idea that use of simvas-
tatin nanoparticles with an anticancer agent can be 
used for patients who have cancer and hyperlipidemic 
conditions. Simvastatin shows both hypolipidemic 
potential and a synergistic effect with an anticancer 
agent. The present study establishes that cubic nano-
particles of simvastatin have significantly better con-
trol over the growth of MCF-7 cells than pure 
simvastatin drug. In future, an in vivo animal model 
study will be required to identify the anticancer effects 
of the anti-hyperlipidemic agent simvastatin.
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